These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2544309)

  • 1. A phase I study of a new 5HT3-receptor antagonist, BRL43694A, an agent for the prevention of chemotherapy-induced nausea and vomiting.
    Falkson G; van Zyl AJ
    Cancer Chemother Pharmacol; 1989; 24(3):193-6. PubMed ID: 2544309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II trial of granisetron: a novel 5-hydroxytryptamine antagonist for the prevention of chemotherapy-induced nausea and vomiting.
    Addelman M; Erlichman C; Fine S; Warr D; Murray C
    J Clin Oncol; 1990 Feb; 8(2):337-41. PubMed ID: 2153767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeated use of granisetron in patients receiving cytostatic agents.
    de Wet M; Falkson G; Rapoport BL
    Cancer; 1993 Jun; 71(12):4043-9. PubMed ID: 8389659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.
    Warr D; Willan A; Fine S; Wilson K; Davis A; Erlichman C; Rusthoven J; Lofters W; Osoba D; Laberge F
    J Natl Cancer Inst; 1991 Aug; 83(16):1169-73. PubMed ID: 1653363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [BRL 43694A--a 5-hydroxytryptamine receptor blocker as an antiemetic in cytostatic therapy].
    Joss R; Rohrbach D; Buser K; Pirovino M; Karde C; Brunner K
    Schweiz Med Wochenschr; 1989 Jun; 119(23):831-4. PubMed ID: 2549616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
    Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
    Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High versus low dose granisetron, a selective 5HT3 antagonist, for the prevention of chemotherapy-induced nausea and vomiting.
    Falkson HC; Falkson CI; Falkson G
    Invest New Drugs; 1990 Nov; 8(4):407-9. PubMed ID: 1964678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical evaluation of antiemetic effects of 5-hydroxytryptamine receptor type 3 (5HT3 receptor) antagonists based on changes in eating condition in cancer patients receiving chemotherapy].
    Okuyama K; Yoshimoto K; Iwase O; Ozeki T; Yamada Y
    Yakugaku Zasshi; 2008 Apr; 128(4):649-55. PubMed ID: 18379183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The antiemetic action of tropisetron (Navoban) in the cytostatic treatment of neoplastic diseases].
    Buiuc AI; Găleşanu MR
    Rev Med Chir Soc Med Nat Iasi; 1996; 100(3-4):160-4. PubMed ID: 9455457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of granisetron in the prevention of chemotherapy-induced emesis in paediatric patients.
    Lemerle J; Amaral D; Southall DP; Upward J; Murdoch RD
    Eur J Cancer; 1991; 27(9):1081-3. PubMed ID: 1659848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiemetic control: 5-HT3 antagonists: review of clinical results, with particular emphasis on ondansetron.
    Kidgell AE; Butcher ME; Brown GW
    Cancer Treat Rev; 1990 Sep; 17(2-3):311-7. PubMed ID: 2176933
    [No Abstract]   [Full Text] [Related]  

  • 12. Granisetron (BRL 43694) in the treatment of cytostatic drug-induced emesis: a summary.
    Pintens H
    Cancer Treat Rev; 1990 Sep; 17(2-3):307-10. PubMed ID: 2176932
    [No Abstract]   [Full Text] [Related]  

  • 13. [Medical treatment of chemotherapy-induced nausea and vomiting].
    Herrstedt J
    Ugeskr Laeger; 2007 Feb; 169(9):799-805. PubMed ID: 17355844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRL 43694: a novel antiemetic to prevent nausea and vomiting induced by chemotherapy.
    Joss RA; Richner J; Brunner KW; Rohrbach D; Pirovino M; Terrey JP; Upward J
    J Natl Cancer Inst; 1988 Oct; 80(16):1340-1. PubMed ID: 2845107
    [No Abstract]   [Full Text] [Related]  

  • 15. [Comparison of 1 mg/body and 3 mg/body of intravenous granisetron for the prevention of chemotherapy-induced nausea and vomiting and adverse events in hematological malignancy patients].
    Motohashi S; Hori K; Ono T; Ohnishi K; Kawakami J
    Yakugaku Zasshi; 2012; 132(5):675-81. PubMed ID: 22687700
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. The Granisetron Study Group.
    Marty M
    Eur J Cancer; 1992; 28A Suppl 1():S12-6. PubMed ID: 1320913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study on the inhibitory effect of a 5-HT3 antagonist, granisetron, for nausea and vomiting induced by chemotherapy (CHOP, VEPA, high-dose ETP) for non-Hodgkin's lymphoma].
    Sasai Y; Misawa S; Iwai T; Tamura A; Nakazawa N; Ueda Y; Kaneko H; Horiike S; Yokota S; Taniwaki M; Kashima K; Tsuda S; Ookawara Y; Nakao M; Nakagawa H; Fujii H
    Gan To Kagaku Ryoho; 1998 Apr; 25(5):723-9. PubMed ID: 9571970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The prevention and treatment of nausea and vomiting during cancer chemotherapy].
    Shparyk IaV; Bilyns'kyĭ BT; Koval'chuk IV; Petriv RM; Kachmar TB; Ohorchak MA
    Lik Sprava; 1997; (4):148-52. PubMed ID: 9471361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
    Sigsgaard T; Herrstedt J; Andersen LJ; Havsteen H; Langer SW; Kjaerbøl AG; Lund H; Kjaer M; Dombernowsky P
    Br J Cancer; 1999 May; 80(3-4):412-8. PubMed ID: 10408847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.